Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

extraskeletal myxoid chondrosarcoma - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

extraskeletal myxoid chondrosarcoma

MONDO:0012825

Also known as:extraosseous chondrosarcomaextraskeletal chondrosarcomamyxoid extraosseous chondrosarcoma

Find Clinical TrialsTrials

Overview

A rare malignant soft tissue neoplasm of uncertain differentiation, characterized by the presence of chondroblast-like cells in a myxoid stroma and a multinodular growth pattern. The most common sites of involvement are the deep soft tissues of the extremities, particularly the thigh. It usually presents as an enlarging soft tissue mass. Patients may have long survivals, but local recurrences and metastases occur in approximately half of the cases. The most common site of metastasis is the lungs.

GeneticsMultifactorial · NR4A3 (chr 9)

Clinical Trials5 registered · 1 recruiting

Clinical Presentation

Features include: Chondrosarcoma.

Explore clinical features

Genetic Landscape

Assembled from HGNC gene records, ClinGen gene-disease validity evidence, and ClinVar pathogenic variant data. Validity classifications reflect the strength of published evidence linking each gene to this disease.

NR4A3 encodes nuclear receptor subfamily 4 group A member 3 (626 aa). Transcriptional activator that binds to regulatory elements in promoter regions in a cell- and response element (target)-specific manner. Highest expression in Artery Tibial (41.6 TPM) and Adipose Visceral Omentum (35.6 TPM).

Extraskeletal myxoid chondrosarcoma is associated with mutations in the NR4A3 gene on chromosome 9.

The NR4A3 protein participates in NR4A3 gene expression is stimulated by RUNX1:CBFB, RUNX1:CBFB:NR4A3 gene, and RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function pathways.

NR4A3 is classified as a druggable target (Clinically Actionable, Druggable Genome, Nuclear Hormone Receptor, Transcription Factor, Transcription Factor Complex, and Transporter categories) with score 3.2.

Diagnosis

Genetic testing for NR4A3 is available. Testing is considered confirmatory for diagnosis.

Biomarker and diagnostic research for extraskeletal myxoid chondrosarcoma has been reported in the published literature.

Prognosis

Estimated prevalence: 1-9 in 1,000,000 (Rare).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

5 clinical trials registered, 1 recruiting. Interventions under study include procedural interventions, drug therapy, other interventions, and biologic therapy. Pipeline includes 2 PHASE2, 1 PHASE1, 1 NA. Research is primarily sponsored by academic and government institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT06526897](https://clinicaltrials.gov/study/NCT06526897)

Data assembled from 7 of 12 sources · Last updated Nov 2, 2026, 10:23 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

OMIM

Online Mendelian Inheritance in Man

OMIM:612237

Orphanet

European rare disease database

Orphanet:209916

GARD

Genetic and Rare Diseases Info Center

GARD:17105

Questions for Your Care Team

→Are any of the 5 active clinical trials a good fit for my situation?
→Should I pursue genetic testing for NR4A3, and what would the results mean for my family?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Patient case studies	17	53%
Testing and diagnosis research	6	19%
Laboratory research	5	16%
Clinical study results	2	6%
Research summaries	1	3%
Disease patterns and progression	1	3%

Kisho

extraskeletal myxoid chondrosarcoma

Overview

Clinical Presentation

Explore clinical features

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Recent Publications

Latest News & Developments

Recurrent Dedifferentiated Clival Chondrosarcoma Presenting 32 Years after Initial Treatment: A Case Report.

extraskeletal myxoid chondrosarcoma

Overview

Clinical Presentation

Explore clinical features

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Recent Publications

Latest News & Developments

Recurrent Dedifferentiated Clival Chondrosarcoma Presenting 32 Years after Initial Treatment: A Case Report.